Verve Therapeutics Announces Positive Initial Data from the Heart-2 Phase 1b Clinical Trial of VERVE-102, an In Vivo Base Editing Medicine Targeting PCSK9

Verve Therapeutics has announced positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102, a single-dose base editing treatment targeting PCSK9 for cardiovascular disease. The trial included 14 participants with heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD).